GRF:BME
Grifols SA Class A
€9.53
arrow_downward
-0.67%(-0.064) 1D
Oct 2, 5:36:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRF...
Open
€9.57
High
€9.71
Low
€9.48
Mkt. cap
5.77B
Avg. vol.
1.13M
Volume
969.03K
Dividend
2.44%
Quarterly dividend
€0.06
Ex-dividend date
Jun 30, 2026
P/E ratio
14.34
52-wk high
€12.87
52-wk low
€8.43
EPS
€0.67
Shares outstanding
426.13M
No. of employees
25K
Open
€9.57
High
€9.71
Low
€9.48
Mkt. cap
5.77B
Avg. vol.
1.13M
Volume
969.03K
Dividend
2.44%
Quarterly dividend
€0.06
Ex-dividend date
Jun 30, 2026
P/E ratio
14.34
52-wk high
€12.87
52-wk low
€8.43
EPS
€0.67
Shares outstanding
426.13M
No. of employees
25K
News stories
From web sources and news partners
AD HOC NEWS
·
1 hour ago
Grifols says Canada license suspension has no impact; Grifols stock costs EUR 9.52
The New York Times
·
1 month ago
After 2 Plasma Donor Deaths, Company Pauses Clinics in Canada
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA Class A